Search results
Results from the WOW.Com Content Network
There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates ...
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
The cancer drug has been Merck's top-selling medicine and its biggest growth driver -- by a mile. ... Should you invest $1,000 in Merck right now? Before you buy stock in Merck, consider this:
Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500. Why isn't Merck's stock doing better in ...
Keytruda has been the best-selling medicine in the world since last year, when it generated $25 billion in sales. Merck's total revenue for the year was $60.1 billion, so Keytruda accounted for ...
Merck & Co. (NYSE: MRK), a pharmaceutical giant known for its cancer immunotherapy drug Keytruda, has seen its stock surge 16.8% year-to-date. This impressive run follows aggressive buying by a ...
Before you buy stock in Merck, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Merck wasn’t one ...
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% ...